Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden
Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå Universit...
Ausführliche Beschreibung
Autor*in: |
Lindmark K [verfasserIn] Boman K [verfasserIn] Olofsson M [verfasserIn] Törnblom M [verfasserIn] Levine A [verfasserIn] Castelo-Branco A [verfasserIn] Schlienger R [verfasserIn] Bruce Wirta S [verfasserIn] Stålhammar J [verfasserIn] Wikström G [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2019 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Clinical Epidemiology - Dove Medical Press, 2009, (2019), Seite 231-244 |
---|---|
Übergeordnetes Werk: |
year:2019 ; pages:231-244 |
Links: |
---|
Katalog-ID: |
DOAJ048163546 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ048163546 | ||
003 | DE-627 | ||
005 | 20230503011933.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2019 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ048163546 | ||
035 | |a (DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC109-216 | |
100 | 0 | |a Lindmark K |e verfasserin |4 aut | |
245 | 1 | 0 | |a Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world | ||
650 | 4 | |a diagnosis | |
650 | 4 | |a heart failure | |
650 | 4 | |a incidence | |
650 | 4 | |a mortality | |
650 | 4 | |a prevalence | |
650 | 4 | |a Sweden | |
653 | 0 | |a Infectious and parasitic diseases | |
700 | 0 | |a Boman K |e verfasserin |4 aut | |
700 | 0 | |a Olofsson M |e verfasserin |4 aut | |
700 | 0 | |a Törnblom M |e verfasserin |4 aut | |
700 | 0 | |a Levine A |e verfasserin |4 aut | |
700 | 0 | |a Castelo-Branco A |e verfasserin |4 aut | |
700 | 0 | |a Schlienger R |e verfasserin |4 aut | |
700 | 0 | |a Bruce Wirta S |e verfasserin |4 aut | |
700 | 0 | |a Stålhammar J |e verfasserin |4 aut | |
700 | 0 | |a Wikström G |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Clinical Epidemiology |d Dove Medical Press, 2009 |g (2019), Seite 231-244 |w (DE-627)600305392 |w (DE-600)2494772-6 |x 11791349 |7 nnns |
773 | 1 | 8 | |g year:2019 |g pages:231-244 |
856 | 4 | 0 | |u https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6 |z kostenfrei |
856 | 4 | 0 | |u https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1179-1349 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |j 2019 |h 231-244 |
author_variant |
l k lk b k bk o m om t m tm l a la c b a cba s r sr b w s bws s j sj w g wg |
---|---|
matchkey_str |
article:11791349:2019----::pdmooyferfiuentedidansiwruaersetvpplt |
hierarchy_sort_str |
2019 |
callnumber-subject-code |
RC |
publishDate |
2019 |
allfields |
(DE-627)DOAJ048163546 (DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6 DE-627 ger DE-627 rakwb eng RC109-216 Lindmark K verfasserin aut Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world diagnosis heart failure incidence mortality prevalence Sweden Infectious and parasitic diseases Boman K verfasserin aut Olofsson M verfasserin aut Törnblom M verfasserin aut Levine A verfasserin aut Castelo-Branco A verfasserin aut Schlienger R verfasserin aut Bruce Wirta S verfasserin aut Stålhammar J verfasserin aut Wikström G verfasserin aut In Clinical Epidemiology Dove Medical Press, 2009 (2019), Seite 231-244 (DE-627)600305392 (DE-600)2494772-6 11791349 nnns year:2019 pages:231-244 https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6 kostenfrei https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP kostenfrei https://doaj.org/toc/1179-1349 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 231-244 |
spelling |
(DE-627)DOAJ048163546 (DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6 DE-627 ger DE-627 rakwb eng RC109-216 Lindmark K verfasserin aut Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world diagnosis heart failure incidence mortality prevalence Sweden Infectious and parasitic diseases Boman K verfasserin aut Olofsson M verfasserin aut Törnblom M verfasserin aut Levine A verfasserin aut Castelo-Branco A verfasserin aut Schlienger R verfasserin aut Bruce Wirta S verfasserin aut Stålhammar J verfasserin aut Wikström G verfasserin aut In Clinical Epidemiology Dove Medical Press, 2009 (2019), Seite 231-244 (DE-627)600305392 (DE-600)2494772-6 11791349 nnns year:2019 pages:231-244 https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6 kostenfrei https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP kostenfrei https://doaj.org/toc/1179-1349 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 231-244 |
allfields_unstemmed |
(DE-627)DOAJ048163546 (DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6 DE-627 ger DE-627 rakwb eng RC109-216 Lindmark K verfasserin aut Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world diagnosis heart failure incidence mortality prevalence Sweden Infectious and parasitic diseases Boman K verfasserin aut Olofsson M verfasserin aut Törnblom M verfasserin aut Levine A verfasserin aut Castelo-Branco A verfasserin aut Schlienger R verfasserin aut Bruce Wirta S verfasserin aut Stålhammar J verfasserin aut Wikström G verfasserin aut In Clinical Epidemiology Dove Medical Press, 2009 (2019), Seite 231-244 (DE-627)600305392 (DE-600)2494772-6 11791349 nnns year:2019 pages:231-244 https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6 kostenfrei https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP kostenfrei https://doaj.org/toc/1179-1349 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 231-244 |
allfieldsGer |
(DE-627)DOAJ048163546 (DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6 DE-627 ger DE-627 rakwb eng RC109-216 Lindmark K verfasserin aut Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world diagnosis heart failure incidence mortality prevalence Sweden Infectious and parasitic diseases Boman K verfasserin aut Olofsson M verfasserin aut Törnblom M verfasserin aut Levine A verfasserin aut Castelo-Branco A verfasserin aut Schlienger R verfasserin aut Bruce Wirta S verfasserin aut Stålhammar J verfasserin aut Wikström G verfasserin aut In Clinical Epidemiology Dove Medical Press, 2009 (2019), Seite 231-244 (DE-627)600305392 (DE-600)2494772-6 11791349 nnns year:2019 pages:231-244 https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6 kostenfrei https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP kostenfrei https://doaj.org/toc/1179-1349 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 231-244 |
allfieldsSound |
(DE-627)DOAJ048163546 (DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6 DE-627 ger DE-627 rakwb eng RC109-216 Lindmark K verfasserin aut Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world diagnosis heart failure incidence mortality prevalence Sweden Infectious and parasitic diseases Boman K verfasserin aut Olofsson M verfasserin aut Törnblom M verfasserin aut Levine A verfasserin aut Castelo-Branco A verfasserin aut Schlienger R verfasserin aut Bruce Wirta S verfasserin aut Stålhammar J verfasserin aut Wikström G verfasserin aut In Clinical Epidemiology Dove Medical Press, 2009 (2019), Seite 231-244 (DE-627)600305392 (DE-600)2494772-6 11791349 nnns year:2019 pages:231-244 https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6 kostenfrei https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP kostenfrei https://doaj.org/toc/1179-1349 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2019 231-244 |
language |
English |
source |
In Clinical Epidemiology (2019), Seite 231-244 year:2019 pages:231-244 |
sourceStr |
In Clinical Epidemiology (2019), Seite 231-244 year:2019 pages:231-244 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
diagnosis heart failure incidence mortality prevalence Sweden Infectious and parasitic diseases |
isfreeaccess_bool |
true |
container_title |
Clinical Epidemiology |
authorswithroles_txt_mv |
Lindmark K @@aut@@ Boman K @@aut@@ Olofsson M @@aut@@ Törnblom M @@aut@@ Levine A @@aut@@ Castelo-Branco A @@aut@@ Schlienger R @@aut@@ Bruce Wirta S @@aut@@ Stålhammar J @@aut@@ Wikström G @@aut@@ |
publishDateDaySort_date |
2019-01-01T00:00:00Z |
hierarchy_top_id |
600305392 |
id |
DOAJ048163546 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048163546</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503011933.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048163546</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Lindmark K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael T&ouml;rnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan St&aring;lhammar,6 Gerhard Wikstr&ouml;m7 1Department of Public Health and Clinical Medicine and Heart Centre, Ume&aring; University Hospital, Ume&aring;, Sweden; 2Research Unit, Medicine-Geriatric, Skellefte&aring; County Hospital, Department of Public Health and Clinical Medicine, Ume&aring; University, Ume&aring;, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (&ge;2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005&ndash;2013) and electronic medical records (cohort 2, 2010&ndash;2015; primary/secondary care patients from Uppsala and V&auml;sterbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged &ge;85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06&ndash;1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02&ndash;1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997&ndash;2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P&lt;0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">incidence</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mortality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prevalence</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sweden</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Boman K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Olofsson M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Törnblom M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Levine A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Castelo-Branco A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schlienger R</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bruce Wirta S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stålhammar J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wikström G</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Clinical Epidemiology</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2019), Seite 231-244</subfield><subfield code="w">(DE-627)600305392</subfield><subfield code="w">(DE-600)2494772-6</subfield><subfield code="x">11791349</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2019</subfield><subfield code="g">pages:231-244</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1179-1349</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2019</subfield><subfield code="h">231-244</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Lindmark K |
spellingShingle |
Lindmark K misc RC109-216 misc diagnosis misc heart failure misc incidence misc mortality misc prevalence misc Sweden misc Infectious and parasitic diseases Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden |
authorStr |
Lindmark K |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)600305392 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC109-216 |
illustrated |
Not Illustrated |
issn |
11791349 |
topic_title |
RC109-216 Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden diagnosis heart failure incidence mortality prevalence Sweden |
topic |
misc RC109-216 misc diagnosis misc heart failure misc incidence misc mortality misc prevalence misc Sweden misc Infectious and parasitic diseases |
topic_unstemmed |
misc RC109-216 misc diagnosis misc heart failure misc incidence misc mortality misc prevalence misc Sweden misc Infectious and parasitic diseases |
topic_browse |
misc RC109-216 misc diagnosis misc heart failure misc incidence misc mortality misc prevalence misc Sweden misc Infectious and parasitic diseases |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Clinical Epidemiology |
hierarchy_parent_id |
600305392 |
hierarchy_top_title |
Clinical Epidemiology |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)600305392 (DE-600)2494772-6 |
title |
Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden |
ctrlnum |
(DE-627)DOAJ048163546 (DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6 |
title_full |
Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden |
author_sort |
Lindmark K |
journal |
Clinical Epidemiology |
journalStr |
Clinical Epidemiology |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2019 |
contenttype_str_mv |
txt |
container_start_page |
231 |
author_browse |
Lindmark K Boman K Olofsson M Törnblom M Levine A Castelo-Branco A Schlienger R Bruce Wirta S Stålhammar J Wikström G |
class |
RC109-216 |
format_se |
Elektronische Aufsätze |
author-letter |
Lindmark K |
author2-role |
verfasserin |
title_sort |
epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in sweden |
callnumber |
RC109-216 |
title_auth |
Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden |
abstract |
Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world |
abstractGer |
Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world |
abstract_unstemmed |
Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael Törnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan Stålhammar,6 Gerhard Wikström7 1Department of Public Health and Clinical Medicine and Heart Centre, Umeå University Hospital, Umeå, Sweden; 2Research Unit, Medicine-Geriatric, Skellefteå County Hospital, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (≥2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005–2013) and electronic medical records (cohort 2, 2010–2015; primary/secondary care patients from Uppsala and Västerbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged ≥85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06–1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02–1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997–2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P<0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
title_short |
Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden |
url |
https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6 https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP https://doaj.org/toc/1179-1349 |
remote_bool |
true |
author2 |
Boman K Olofsson M Törnblom M Levine A Castelo-Branco A Schlienger R Bruce Wirta S Stålhammar J Wikström G |
author2Str |
Boman K Olofsson M Törnblom M Levine A Castelo-Branco A Schlienger R Bruce Wirta S Stålhammar J Wikström G |
ppnlink |
600305392 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
callnumber-a |
RC109-216 |
up_date |
2024-07-03T16:16:56.541Z |
_version_ |
1803575274023944192 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048163546</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503011933.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048163546</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd47ebafe9ead4996bdf5c097e3bda9f6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Lindmark K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Krister Lindmark,1 Kurt Boman,2 Mona Olofsson,2 Michael T&ouml;rnblom,3 Aaron Levine,3 Anna Castelo-Branco,3 Raymond Schlienger,4 Sara Bruce Wirta,5 Jan St&aring;lhammar,6 Gerhard Wikstr&ouml;m7 1Department of Public Health and Clinical Medicine and Heart Centre, Ume&aring; University Hospital, Ume&aring;, Sweden; 2Research Unit, Medicine-Geriatric, Skellefte&aring; County Hospital, Department of Public Health and Clinical Medicine, Ume&aring; University, Ume&aring;, Sweden; 3Real-World & Analytics Solutions, IQVIA, Solna, Sweden; 4Quantitative Safety & Epidemiology, Novartis Pharma AG, Basel, Switzerland; 5Global RWE Cardio-Metabolics, Novartis Sweden AB, Stockholm, Sweden; 6Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 7Department for Medical Sciences, Uppsala University, Uppsala, Sweden Purpose: The purpose of this study was to examine the trends in heart failure (HF) epidemiology and diagnostic work-up in Sweden.Methods: Adults with incident HF (&ge;2 ICD-10 diagnostic codes) were identified from linked national health registers (cohort 1, 2005&ndash;2013) and electronic medical records (cohort 2, 2010&ndash;2015; primary/secondary care patients from Uppsala and V&auml;sterbotten). Trends in annual HF incidence rate and prevalence, risk of all-cause and cardiovascular disease (CVD)-related 1-year mortality and use of diagnostic tests 6 months before and after first HF diagnosis (cohort 2) were assessed.Results: Baseline demographic and clinical characteristics were similar for cohort 1 (N=174,537) and 2 (N=8,702), with mean ages of 77.4 and 76.6 years, respectively; almost 30% of patients were aged &ge;85 years. From 2010 to 2014, age-adjusted annual incidence rate of HF/1,000 inhabitants decreased (from 3.20 to 2.91, cohort 1; from 4.34 to 3.33, cohort 2), while age-adjusted prevalence increased (from 1.61% to 1.72% and from 2.15% to 2.18%, respectively). Age-adjusted 1-year all-cause and CVD-related mortality was higher in men than in women among patients in cohort 1 (all-cause mortality hazard ratio [HR] men vs women 1.07 [95% CI 1.06&ndash;1.09] and CVD-related mortality subdistribution HR for men vs women 1.04 [95% CI 1.02&ndash;1.07], respectively). While 83.5% of patients underwent N-terminal pro-B-type natriuretic peptide testing, only 36.4% of patients had an echocardiogram at the time of diagnosis, although this increased overtime. In the national prevalent HF population (patients with a diagnosis in 1997&ndash;2004 who survived into the analysis period; N=273,999), death from ischemic heart disease and myocardial infarction declined between 2005 and 2013, while death from HF and atrial fibrillation/flutter increased (P&lt;0.0001 for trends over time). Conclusion: The annual incidence rate of HF declined over time, while prevalence of HF has increased, suggesting that patients with HF were surviving longer over time. Our study confirms that previously reported epidemiological trends persist and remain to ensure proper diagnostic evaluation and management of patients with HF. Keywords: diagnosis, heart failure, incidence rate, mortality, prevalence, real-world</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">incidence</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mortality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prevalence</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sweden</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Boman K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Olofsson M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Törnblom M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Levine A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Castelo-Branco A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schlienger R</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bruce Wirta S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stålhammar J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wikström G</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Clinical Epidemiology</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2019), Seite 231-244</subfield><subfield code="w">(DE-627)600305392</subfield><subfield code="w">(DE-600)2494772-6</subfield><subfield code="x">11791349</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2019</subfield><subfield code="g">pages:231-244</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d47ebafe9ead4996bdf5c097e3bda9f6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/epidemiology-of-heart-failure-and-trends-in-diagnostic-work-up-a-retro-peer-reviewed-article-CLEP</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1179-1349</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2019</subfield><subfield code="h">231-244</subfield></datafield></record></collection>
|
score |
7.39964 |